Zobrazeno 1 - 10
of 560
pro vyhledávání: '"programmed cell death ligand-1"'
Publikováno v:
Journal of Hepatocellular Carcinoma, Vol Volume 11, Pp 1823-1833 (2024)
Yang Xie, Xiangyang Sun, Fubo Xie, Wencheng Jian, Qingliang Wang, Xiaochen Ma, Caixia Li, Kai Zhang Department of Radiology, Qilu Hospital of Shandong University, Shandong, People’s Republic of ChinaCorrespondence: Kai Zhang, Department of Radiolog
Externí odkaz:
https://doaj.org/article/9ab0545e3b974bbea80a71b85e834db2
Publikováno v:
BMC Medical Imaging, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Objective To assess whether diffusion and perfusion MRI derived parameters could non-invasively predict PD-L1 and Ki-67 status in primary central nervous system diffuse large B-cell lymphoma (PCNS-DLBCL). Methods We retrospectively analyzed
Externí odkaz:
https://doaj.org/article/eb73786e08924712a88236d37ae62c9b
Autor:
Atsushi Ito, Shu Kano, Tomohito Tarukawa, Yuta Suzuki, Tadashi Sakaguchi, Kentaro Ito, Yoichi Nishii, Osamu Taguchi, Hiroki Yasui, Motoshi Takao, Osamu Hataji
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
ObjectivesThis study aimed to assess the intrinsic impacts of the expression of PD-L1 on postoperative recurrence and the prognosis in patients with epidermal growth factor receptor (EGFR)-mutated lung adenocarcinomas.Patients and methodsData from 22
Externí odkaz:
https://doaj.org/article/c0e0b61e81f84ee6a9005026c1576afa
Publikováno v:
Journal of Clinical and Diagnostic Research, Vol 18, Iss 02, Pp 01-06 (2024)
Head and Neck Squamous Cell Carcinoma (HNSCC) is one of the most common malignancies worldwide with most of the patients presenting in advanced stage. The associated high mortality and poor prognosis of the tumour has rendered the search for better t
Externí odkaz:
https://doaj.org/article/5a24065d835d4aa0965e8fec7aa37619
Publikováno v:
Diagnostic Pathology, Vol 19, Iss 1, Pp 1-8 (2024)
Abstract Background We encountered a cervical lymphoepithelial carcinoma (LEC) possessing a predominantly solid architecture with deficient mismatch repair (dMMR) and loss of expression of the SWI/SNF (SWItch/Sucrose Non-Fermentable) chromatin remode
Externí odkaz:
https://doaj.org/article/ec3284dc3d4c4e3cac8dc79c07417c0c
Autor:
Kashif Asghar, Shaarif Bashir, Muhammad Hassan, Asim Farooq, Muhammad Abu Bakar, Sundus Bilal, Maryam Hameed, Shafqat Mehmood, Asif Loya
Publikováno v:
Egyptian Liver Journal, Vol 14, Iss 1, Pp 1-7 (2024)
Abstract Background Hepatocellular carcinoma (HCC) is a highly aggressive and rapidly progressing form of cancer with a poor prognosis. Recent advances in the management of HCC focused on the novel immunotherapeutic modalities for patients with advan
Externí odkaz:
https://doaj.org/article/027472d467124a5c8def349b5eed74ce
Publikováno v:
Breast Cancer: Targets and Therapy, Vol Volume 16, Pp 1-13 (2024)
Suheyla Ekemen,1,2 Ebru Bilir,3 Hagar Elsayed Akram Soultan,3 Sadia Zafar,3 Figen Demir,4 Babek Tabandeh,5 Sadik Toprak,6 Ozlem Yapicier,7 Cevayir Coban2,8,9 1Vocational School of Health Services, Acibadem University, Istanbul, Turkey; 2Division of M
Externí odkaz:
https://doaj.org/article/95c1f39953ba4d5e89a822ce00ed5b98
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 4, Iss 6, Pp 1301-1309 (2023)
Pembrolizumab combined with chemotherapy has been established as the preferred first-line therapy for treating metastatic triple-negative breast cancer (mTNBC) with programmed cell death ligand-1 (PD-L1)-positive disease since its approval for that i
Externí odkaz:
https://doaj.org/article/daec0b61338044bbb23da71553b951f5
Publikováno v:
The Clinical Respiratory Journal, Vol 18, Iss 4, Pp n/a-n/a (2024)
Abstract Objective Previous studies have shown that immune checkpoint inhibitors can improve the survival of patients with advanced non‐small cell lung cancer with KRAS mutations; however, there is a lack of comparisons between treatment regimens a
Externí odkaz:
https://doaj.org/article/55b74c33b25f4590a3c29a51711597c2
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-12 (2023)
Abstract Introduction The optimal first-line immunotherapy regimen for advanced non-squamous non-small cell lung cancer (NS-NSCLC) patients with programmed cell death ligand 1 (PD-L1) expression ≥ 50% remains unclear. Our aim is to determine the mo
Externí odkaz:
https://doaj.org/article/e0351466e20844bdacf90b847354cc82